Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Fiscal 2026 was defined by the June 25, 2026 agreement to be acquired by Merck KGaA for $73.00 per share in cash, with closing expected in late 2026 or early 2027. Management attributed the year's underlying profit decline to unfavorable product mix and pricing pressures, while reported GAAP operating income more than doubled because the prior year included an $80.5M impairment of assets held-for-sale and a non-recurring arbitration award. Revenue was essentially flat, and adjusted net earnings fell 1% even as reported earnings per share surged. The pending merger makes standalone execution less relevant, but deal termination fees and regulatory approvals introduce uncertainty.
Revenue
$1.22B
-0.38% YoY
EPS (Diluted)
$1.16
+152.17% YoY
Gross Margin
65.8%
+1.0 pts YoY
Operating Income
$251.89M
+146.34% YoY
Audit Opinion: Unqualified opinion on the consolidated financial statements and internal control over financial reporting(Report of Independent Registered Public Accounting Firm)
Source: SEC XBRL
BIO-TECHNE (TECH) reported FY2026 revenue of $1.22B, down 0.4% year over year. Operating margin was 20.7%, up 12.3 points from 8.4% a year earlier. Operating cash flow was $292.07M, up 1.6% year over year.
Last 4 quarters: 2 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Mar 2026 | 0.53 | 0.55 | Miss -3.3% |
| Dec 2025 | 0.46 | 0.44 | Beat +4.0% |
| Sep 2025 | 0.42 | 0.43 | Miss -2.0% |
| Jun 2025 | 0.53 | 0.51 | Beat +4.1% |
2 reported segments · SEC XBRL
Segment revenue totals $1.21B, which is the $1.22B of consolidated revenue on the income statement.
Profit above is reported as operating income, the measure TECH itself discloses in this filing. Each company chooses its own measure here, so these margins are not comparable with another company's.
Compiled by AI from 10-K Item 7 of this filing
On June 25, 2026, Bio-Techne entered a merger agreement under which Merck KGaA will acquire all outstanding shares for $73.00 per share in cash; closing is expected by late 2026 or early 2027, and the company would owe a $230.5M termination fee in certain circumstances.
Source: 10-K Item 7 MD&A
Consolidated organic revenue was flat in fiscal 2026; foreign currency translation added 2%, and a business held-for-sale subtracted 2%. Adjusted net earnings decreased 1% due to unfavorable product mix and pricing pressures.
Source: 10-K Item 7 MD&A
Selling, general and administrative expenses decreased $136.1M (23%) primarily because the prior year included an $80.5M impairment of assets held-for-sale and a non-recurring arbitration award.
Source: 10-K Item 7 MD&A
Cash and equivalents were $264.7M at June 30, 2026, with $200.0M drawn on the revolving credit facility and $800.0M of unutilized availability.
Source: 10-K Item 7 MD&A
The company must acquire the remaining 80.1% of Wilson Wolf on December 31, 2027 (or earlier if milestones are met) for approximately $1B plus potential contingent consideration, forecasted between fiscal 2027 and fiscal 2028.
Source: 10-K Item 7 MD&A
Compiled by AI from 10-K Item 1A of this filing · 3 high, 2 medium, 0 low
Approximately 48% of fiscal 2026 sales came from outside the U.S., with expansion planned in China, India and other developing markets; military conflicts and trade tensions, including Russia's invasion of Ukraine, could disrupt operations and increase compliance costs.
Source: 10-K Item 1A Risk Factors
Products in the diagnostics market depend on government healthcare policies and funding; changes in reimbursement, potential FDA regulation of lab developed tests, and government negotiation of drug prices could reduce demand or increase costs.
Source: 10-K Item 1A Risk Factors
The company must acquire the remaining 80.1% of Wilson Wolf for approximately $1B by the end of calendar 2027; acquisitions and investments may underperform, create integration challenges, or result in goodwill impairment charges (goodwill was $975.4M, about 38% of total assets).
Source: 10-K Item 1A Risk Factors
The company faces competition from startups and large multinationals, as well as low-cost Asian manufacturers; consolidation among customers concentrates purchasing power and increases pricing pressure.
Source: 10-K Item 1A Risk Factors
Many products require complex manufacturing subject to FDA and comparable regulations; use of animal-derived materials adds sourcing, import/export, and compliance risks that could delay shipments or increase costs.
Source: 10-K Item 1A Risk Factors
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 1.22 $B | 1.22 $B | -0.38% |
Cost of Revenue $M | 415.97 $M | 429.36 $M | -3.12% |
Gross Profit $M | 799.07 $M | 790.27 $M | +1.11% |
Operating Income $M | 251.89 $M | 102.26 $M | +146.34% |
EPS (Basic) $ | 1.17 $ | 0.47 $ | +148.94% |
EPS (Diluted) $ | 1.16 $ | 0.46 $ | +152.17% |
SG&A Expense $M | 452.42 $M | 588.52 $M | -23.13% |
Answers draw on this SEC filing and the data on this page
TECH's Q3 FY2026 results show a significant improvement in profitability despite a slight decline in revenue, driven by cost reductions and increased operational efficiency.
TECH's Q2 FY2026 results show a slight decline in revenue but improved operating income and net income, highlighting effective cost management despite revenue pressures.
Other companies in Life Sciences Tools & Services